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Abstract: We have previously found that overexpression of CHF1/Hey2 in the myocardium prevents the development of 
phenylephrine-induced hypertrophy. To identify transcriptional pathways regulated by CHF1/Hey2, we cultured primary 
neonatal mouse cardiac myocytes from wild type and transgenic mice overexpressing CHF1/Hey2 and treated them with 
serum, a potent hypertrophic stimulus. We verified that overexpression of CHF1/Hey2 suppressed cardiac myocyte hyper-
trophy induced by serum and then determined transcriptional profiles by microarray hybridization. We identified and veri-
fied important downstream target genes by single gene analysis and qRT-PCR and then identified important biological 
processes by Gene Set Analysis using Biological Process Gene Sets from the Gene Ontology Consortium. We found that 
CHF1/Hey2 suppresses pathways involved in water transport, adenylate cyclase activity, embryonic eye morphogenesis, 
gut development and fluid transport after serum stimulation. Genes involved in protein dephosphorylation, demonstrate 
increased expression in myocytes overexpressing CHF1/Hey2, independent of serum treatment. Genes overexpressed 
prior to serum treatment are involved in regulation of transcription factor activity, nuclear protein export and steroid hor-
mone receptor signaling. Genes overexpressed after serum treatment are involved in autophagy, apoptosis and mitochon-
drial biogenesis. 
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INTRODUCTION 
  Cardiac hypertrophy is an important biological process in 
which individual cardiac myocytes enlarge in response to 
exogenous stimuli. Enlargement of myocytes is associated 
with an increased number of sarcomeres, myofibrils and in-
creasing myocyte width, resulting in an increased ventricular 
wall thickness. Although hypertrophy is initially compensa-
tory, prolonged exposure to hypertrophic stimuli can ulti-
mately lead to contractile dysfunction and apoptotic cell 
death, resulting in cardiac failure and fibrosis. Heart failure 
is a leading cause of morbidity and mortality in Western So-
ciety, with the incidence increasing every year. Understand-
ing the molecular basis for the development of hypertrophy, 
its progression to heart failure and the biological pathways 
involved in this syndrome will have important preventative, 
diagnostic and therapeutic implications.  
  We have previously reported that the Hairy-related 
bHLH transcriptional repressor, CHF1 (also called Hey2, 
Hesr-2, Hrt2, HERP1 and gridlock), functions as a suppres-
sor of cardiac hypertrophy induced by phenylephrine [1]. 
Suppression of cardiac hypertrophy is mediated, at least in 
part, by the binding of CHF1/Hey2 to the transcription factor  
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GATA4, thereby inhibiting the ability of GATA4 to activate 
atrial natriuretic factor (ANF) gene expression along with 
other genes associated with cardiac hypertrophy [1-3]. 
CHF1/Hey2 is normally expressed in the developing heart 
and vasculature and plays a critical role in heart develop-
ment, possibly as an effector of Notch signaling, as previ-
ously described [4-12]. Additional studies have underscored 
the importance of CHF1/Hey2 in the development of the 
myocardium, as loss of CHF1/Hey2 leads to a thin walled 
myocardium [13], cardiomyopathy [10] and ectopic expres-
sion of atrial genes in the ventricular myocardium [14, 15]. 
  In order to identify pathways relevant to cardiac hyper-
trophy in the cardiac myocyte transcriptome that are regu-
lated by CHF1/Hey2, we examined the expression of genes 
in isolated wild type and transgenic myocytes treated with 
serum, a potent hypertrophic stimulus. Here we report that 
CHF1/Hey2 suppresses the adenylate cyclase pathway, 
genes involved in water transport and activates cellular 
phosphatases and genes involved in autophagy. These find-
ings suggest important new pathways in regulation of hyper-
trophy.  
MATERIALS AND METHODS 
Transgenic Mice, Neonatal Mouse Myocyte Culture and 
In Vitro Hypertrophy Assays 
  Transgenic mice overexpressing CHF1/Hey2 in the myo-
cardium under the control of the mlc2v promoter and neona-288    Current Genomics, 2010, Vol. 11, No. 4  Yu et al. 
tal mouse cardiac myocyte culture was performed as previ-
ously described [1]. The purity of each preparation was veri-
fied by immunostaining with an antibody against sarcomeric 
myosin (MF-20, Developmental Studies Hybridoma Bank) 
to be greater than 95%. To induce hypertrophy, neonatal 
myocytes in serum free medium were exposed to media with 
20% fetal bovine serum for 24-48 hours. Hypertrophy was 
assessed at 48 hours by immunostaining cells with a mono-
clonal antibody against sarcomeric myosin (MF-20, Devel-
opmental Studies Hybridoma Bank), digital image capture 
and cell size planimetry as previously described [1]. To iden-
tify important transcriptional pathways involved in hypertro-
phy, RNA was harvested 24 hours after treatment as de-
scribed below. 
RNA Isolation and Microarray Analysis 
  RNA was isolated from cultured myocytes by extraction 
with a commercially available kit (Qiagen) according to the 
manufacturer’s instructions. For microarray hybridization, 
RNA was processed for hybridization to Affymetrix 
GeneChip® Mouse Gene 1.0 ST Arrays through a core facil-
ity in the Functional Genomics Laboratory at the Center for 
Ecogenetics and Environmental Health at the University of 
Washington, as previously described [16] and according to 
the manufacturer’s instructions. The number of independent 
cultures that were harvested for RNA and processed for each 
condition is as follows: WT no serum, 5; WT with serum, 7; 
TG no serum, 6; TG with serum, 7. 
  Raw microarray data was processed with Affymetrix
® 
Expression Console™ Software using Robust Multichip 
Analysis (RMA). Normalized data was analyzed first by 
single gene analysis and then by Gene Set Analysis [17], a 
modification of Gene Set Enrichment Analysis [18]. Selected 
genes were validated by qRT-PCR as previously described 
[19]. A full description of the Gene Set Analysis method is 
available online at http://www-stat.stanford.edu/~tibs/GSA/. 
Gene sets for analysis were obtained from the Gene Ontol-
ogy Project (www.geneontology.org). We focused specifi-
cally on gene sets organized according to Biological Process 
(BP; Gene Ontology). Gene sets were considered to be sig-
nificantly altered when their statistical p values and false 
discovery rates as determined by the software were <0.001. 
All microarray data have been deposited in the Gene Expres-
sion Omnibus Database under accession number GSE14288. 
RESULTS 
Cardiac Myocytes that Overexpress CHF1/Hey2 are   
Resistant to Serum Induced Hypertrophy In Vitro 
  We previously reported that overexpression of 
CHF1/Hey2 in myocytes suppresses hypertrophy induced by 
phenylephrine  in vivo and in vitro [1]. To verify that this 
resistance to hypertrophy is a general phenomenon in re-
sponse to diverse stimuli, we induced hypertrophy of cul-
tured WT and TG cardiac myocytes with 20% serum, a po-
tent inducer of hypertrophy. As shown in Fig. (1), WT myo-
cytes developed increased cell size within 48 hours, as ex-
pected. TG myocytes, in contrast, did not develop increased 
cell size. These findings are consistent with our earlier pub-
lished results and provide the rationale for the transcriptional 
profiling studies outlined below. 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Overexpression of CHF1/Hey2 in cardiac myocytes sup-
presses serum-induced hypertrophy in vitro. Cultured WT and TG 
myocytes were treated with either vehicle or 20% FCS for 48 hours 
and then immunostained with MF-20 antibody against sarcomeric 
myosin to distinguish myocytes from contaminating fibroblasts. 
Cell area was calculated for 50 cells per experiment for three inde-
pendent experiments by digital image capture and planimetry. Sta-
tistical comparison of average cell size was assessed by a student’s 
t-test with statistical significance defined as p < 0.05. 
Transcriptional Profiling of Wild Type and Transgenic 
Myocytes Before and After Serum Stimulation Reveals 
Alterations in Specific Gene Sets that are Both Serum-
Independent and Serum-Dependent 
  To identify the potential downstream targets of 
CHF1/Hey2 that may play a role in the myocyte hypertro-
phic response, we analyzed transcriptional profiles from wild 
type and transgenic myocytes before and after serum stimu-
lation. Both single gene analysis (SGA) as well as cate-
gory/pathway analysis was performed. SGA assesses statisti-
cal significance of each gene on the array separately. This 
approach identified only one gene (CHF1/Hey2, p value < 
0.0001, log2FC = 1.58, ~ 3 fold increased, data not shown) as 
differentially expressed in unstimulated CHF1/Hey2 trans-
genic versus wildtype cells. This finding is consistent with 
our earlier published results that myocardial overexpression 
of CHF1/Hey2 does not result in any significant baseline 
phenotype [1].  
  Analysis of gene expression profiles in serum stimulated 
cells revealed several individual genes that show signifi-
cantly changed expression, defined as a p value < 0.0001, as 
shown in Table 1. CHF1/Hey2 is significantly changed, as 
expected. Other genes include Il1f6, Cecr2, Tmc4, Ndufs5, 
Ndufv3 and Efcab2. IL1F6 is a proinflammatory cytokine, 
CECR2 is a transcription factor that interacts with chromatin 
remodeling proteins, while TMC4 is a transmembrane pro-
tein of unknown function. NDUFS5 and NDUFV3 are com-
ponents of the mitochondrial respiratory chain NADH com-
plex I, while EFCAB2 is a putative calcium binding protein 
of unknown function. To validate some of these findings, we 
performed qRT-PCR for CHF1/Hey2, Ndufs5, Nudfv3 and 
Efcab2. As shown in Fig. (2), the mRNA levels are accu-
rately reflected by the microarray data. The roles of these 
potential target genes in cardiac hypertrophy, to the best of 
our knowledge, are unknown, however. CHF1/Hey2 Regulates Hypertrophy  Current Genomics, 2010, Vol. 11, No. 4    289 
Table 1.  Genes Demonstrating Significant Changes in Expression in CHF1/Hey2 Trangenic Myocytes vs Wild Type myocytes After 
Serum Stimulation 
Gene.Accession Gene.Symbol  Gene.Description  logFC  P.Value  FDR 
NM_013904 Hey2    Hairy/enhancer-of-split related with YRPW 
motif 2  
1.814541571 2.73E-07  0.009724348 
NM_019450  Il1f6   Interleukin 1 family, member 6   -0.429964571  1.98E-05  0.117403674 
ENSMUST00000112686 Cecr2    Cat eye syndrome chromosome region,  
candidate 2 homolog (human)  
0.437622286 2.26E-05  0.117403674 
NM_181820  Tmc4   Transmembrane channel-like gene family 4   -0.306575857  2.31E-05  0.117403674 
NM_001030274 Ndufs5    NADH dehydrogenase (ubiquinone) Fe-S  
protein 5  
0.341531429 3.95E-05  0.12082322 
NM_030087 Ndufv3  NADH dehydrognase (ubiquinone)  
flavoprotein 3  
0.347003714 6.16E-05  0.12082322 
NM_026626  Efcab2   EF-hand calcium binding domain 2   0.473221857  6.46E-05  0.12082322 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). qRT-PCR of transcripts identified by microarray single gene analysis validates their expression profiles. RNA was harvested from 
multiple independent preparations of WT and TG cells treated with serum, reverse transcribed and amplified by standard qRT-PCR methods. 
Expression was normalized to GAPDH and compared by the 2
-C
T method as described [19].  290    Current Genomics, 2010, Vol. 11, No. 4  Yu et al. 
  To gain further insight into potential biological pathways 
altered in our transgenic cells relative to the wildtype cells, 
we carried out category/pathway analysis. More specifically, 
we performed Gene Set Analysis (GSA) [17]. In contrast to 
SGA, GSA assesses statistical significance of a gene 
set/pathway as a whole. This analysis allows for identifica-
tion of gene sets/pathways with genes that show coordinated 
changes in expression, even if the changes are modest. SGA 
and GSA are two complementary approaches. SGA identi-
fies any transcript that meets a chosen filtering criteria such 
as a specific p-value cutoff independent of a pathway con-
tent, whereas GSA identifies gene sets/pathways with genes 
that share a common functional theme. We examined gene 
sets organized by Gene Ontology Biological Process (BP). 
Table 2 lists gene sets with p<0.001. GSA reveals suppres-
sion of gene sets involved in embryonic eye morphogenesis, 
gut development, water transport, fluid transport and regula-
tion of adenylate cyclase activity in the transgenic cells, after 
serum stimulation. Components of these gene sets may be 
direct targets of transcriptional repression by CHF1/Hey2.  
  Analysis of gene sets that are increased in transgenic 
relative to WT cells also revealed a number of interesting 
pathways. In the absence of serum, gene sets involved in 
regulation of transcription factor activity, protein export 
from the nucleus, steroid hormone receptor signaling and 
regulation of protein phosphatase activity are increased. 
Similar gene sets involved in protein dephosphorylation and 
dephosphorylation are increased both in the absence and 
presence of serum. The individual components of these re-
lated gene sets overlap significantly, and their significance 
scores are largely driven by the same genes. In the presence 
of serum, multiple gene sets involved in autophagy, apopto-
sis, mitochondrial biogenesis, cellular component disassem-
bly and viral reproduction demonstrate increased expression. 
Although CHF1/Hey2 is considered to be a transcriptional 
repressor, activation of multiple pathways may reflect either 
positive activation by CHF1/Hey2 or repression of negative 
regulatory factors for these pathways. 
  Analysis of individual components from various BP gene 
sets suppressed by CHF1/Hey2 reveals multiple potential 
targets that may play a role in hypertrophy. These include 
genes involved in water transport (GO:0006833) such as 
aquaporins 2, 3, 5, 6, 7, 8, 9 and 11, suggesting that CHF1/ 
Hey2 globally suppresses water transport and that water 
Table 2.  Gene Ontology Biological Process (BP) Gene Set Changes in CHF1/Hey2 Transgenic Myocytes vs Wild Type Myocytes 
before and/or after Serum Stimulation 
  Tg vs. WT, No Serum  Tg vs. WT, Serum 
GO ID  Biological Process  Size  p-value  FDR  Score  p-value  FDR  Score 
GO:0006470  protein amino acid dephosphorylation  132  <0.001  <0.001  0.5438348  <0.001  <0.001  0.3885387 
GO:0051090  regulation of transcription factor activity  77  <0.001  <0.001  0.4408056  0.465  1.0867179  0.013523 
GO:0006611  protein export from nucleus  20  <0.001  <0.001  0.806123  0.147  0.9996068  0.2632729 
GO:0030518 
steroid hormone receptor signaling  
pathway 
75 <0.001  <0.001  0.3664094  0.159  0.9996068  0.1481744 
GO:0043666 
regulation of phosphoprotein phosphatase 
activity 
10 <0.001  <0.001  1.2864495  0.081  0.9127665  0.5832501 
GO:0016311  dephosphorylation 155  <0.001  <0.001  0.4924526  <0.001  <0.001  0.3715223 
GO:0048048  embryonic eye morphogenesis  10  0.126  0.7716088  -0.3379658  <0.001  <0.001  -0.6525282 
GO:0048565  gut development  33  0.167  0.7736608  -0.1805751  <0.001  <0.001  -0.6338953 
GO:0006833  water transport  16  0.038  0.7716088  -0.8349875  <0.001  <0.001  -1.2825472 
GO:0042044  fluid transport  18  0.064  0.7716088  -0.6696553  <0.001  <0.001  -1.1006198 
GO:0045761  regulation of adenylate cyclase activity  55  0.019  0.7716088  -0.3603997  <0.001  <0.001  -0.7334642 
GO:0016236  macroautophagy 16  0.11  1.0068723  0.3604726  <0.001  <0.001  1.04785 
GO:0000045  autophagosome formation  13  0.074  0.9947778  0.5173092  <0.001  <0.001  1.223408 
GO:0006309  DNA fragmentation during apoptosis  17  0.337  0.8456392  -0.1261624  <0.001  <0.001  0.9596088 
GO:0006921  cell structure disassembly during apoptosis  22 0.214  0.792464  -0.2620884  <0.001  <0.001  0.6978587 
GO:0007005 mitochondrion organization and biogenesis  137 0.09  0.9947778  0.4035484  <0.001  <0.001  0.6073059 
GO:0022411  cellular component disassembly  22  0.214  0.792464  -0.2620884  <0.001  <0.001  0.6978587 
GO:0022415  viral reproductive process  59  0.213  1.074234  0.2154094  <0.001  <0.001  0.4824776 
GO:0030262  apoptotic nuclear changes  25  0.483  1.1064093  0.0040825  <0.001  <0.001  0.6125828 CHF1/Hey2 Regulates Hypertrophy  Current Genomics, 2010, Vol. 11, No. 4    291 
transport may be important for cardiac hypertrophy (Fig. 
(3)). In addition, aquaporins 3, 7 and 9 also transport glyc-
erol and are known as aquaglyceroporins. AQ7 null mice 
develop adipocyte hypertrophy, obesity and diabetes due to 
impaired glycerol efflux [20-22]. These findings raise the 
intriguing possibility that suppression of glycerol efflux in 
cardiac myocytes may prevent the onset of pathological hy-
pertrophy, perhaps through supporting fatty acid metabolism. 
Genes involved in regulation of adenylate cyclase signaling 
(GO:0045761, Fig. (4)) include multiple G protein coupled 
receptors such as ADCYAP1R1, LTB4R2, ADRB2, 
GABBR1, GALR3, GHRHR, CRHR1, ADRA2A, VIPR2, 
GRM4 and intracellular regulators of the adenylate cyclase 
response such as ADCY4, GNAL, ADCY2, ADCY7, 
ADCY1. Given the known role of adrenergic signaling in the 
pathogenesis of cardiac hypertrophy and heart failure (re-
viewed in [23]), suppression of adenylate cyclase activity is 
consistent with these findings. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (4). Heat map for genes related to regulation of adenylate cy-
clase activity (GO: 0045761). Columns represent microarray data 
obtained from independent primary cultures of cells of the indicated 
genotype and therefore represent biological replicates. Gene name 
abbreviations for each component of the gene set are indicated at 
the end of each row. Green indicates expression is lower, while red 
indicates expression is higher than average of WT. The genes in 
this set are predominantly downregulated in the transgenic cells 
(TgS1/2/3/4/5/6/7) in the presence of serum relative to the WT cells 
treated with serum (WTS1/2/3/4/5/6/7). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Heat map for genes involved in water transport (GO: 
0006833). Columns represent microarray data obtained from inde-
pendent primary cultures of cells of the indicated genotype and 
therefore represent biological replicates. Gene name abbreviations 
for each component of the gene set are indicated at the end of each 
row. Green indicates expression is lower, while red indicates ex-
pression is higher than average of WT. The genes in this set are 
predominantly downregulated in the transgenic cells (TgS1/2/3/4/5/ 
6/7) in the presence of serum relative to the WT cells treated with 
serum (WTS1/2/3/4/5/6/7). 292    Current Genomics, 2010, Vol. 11, No. 4  Yu et al. 
  Analysis of individual components of other gene sets 
suppressed in transgenic myocytes after serum stimulation 
reveals a number of interesting regulatory genes. Genes in-
volved in eye development (GO: 0048048) include the tran-
scription factors VAX2, RARG, FOXL2 and SP1 and the 
metabolic enzymes ALDH1A1 and ALDH1A3. Genes in-
volved in gut development (GO: 0048565) include many 
genes known to be important in developmental signaling and 
transcription such as TCF7, NOTCH1, NKX2-3, HOXD13, 
GLI2, FOXF2 and SHH (Fig. (5)). Genes involved in fluid 
transport (GO: 0042044) include the aquaporins described 
above for GO: 0006833 and are largely redundant. A role for 
any of these molecules in cardiac hypertrophy and heart fail-
ure, to the best of our knowledge, has not yet been described. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (5). Heat map for genes pertaining to gut development (GO: 
0048565). Columns represent microarray data obtained from inde-
pendent primary cultures of cells of the indicated genotype and 
therefore represent biological replicates. Gene name abbreviations 
for each component of the gene set are indicated at the end of each 
row. Green indicates expression is lower, while red indicates ex-
pression is higher than average of WT. The genes in this set are 
predominantly downregulated in the transgenic cells (TgS1/2/3/4/5/ 
6/7) in the presence of serum relative to the WT cells treated with 
serum (WTS1/2/3/4/5/6/7). 
  Analysis of individual components of gene sets that are 
activated in the CHF1/Hey2 transgenic myocytes in both the 
absence or presence of serum (GO: 0006470, GO: 0016311) 
reveals a number of phosphatases, such as PTPN4, DUSP28, 
MTMR6, PPP3R1, DUSP8, PPP6C, PPM1B, PPP2R4, 
PPP2R2A and PTPN2 (Fig. (6)). DUSP8 and PPM1B can 
turn off components of the cellular stress response [24, 25], 
while PTPN2 can attenuate EGF signaling [24, 25], both 
which may be relevant to hypertrophy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (6). Heat map for genes linked to protein amino acid dephos-
phorylation (GO: 0006470). Columns represent microarray data 
obtained from independent primary cultures of cells of the indicated 
genotype and therefore represent biological replicates. Gene name 
abbreviations for each component of the gene set are indicated at 
the end of each row. Green indicates expression is lower, while red 
indicates expression is higher than average of WT. The genes in 
this set are predominantly upregulated in the transgenic cells 
(Tg1/2/3/4/5/7) in the absence of serum relative to the correspond-
ing WT cells (WT 1/2/5/6/7).  CHF1/Hey2 Regulates Hypertrophy  Current Genomics, 2010, Vol. 11, No. 4    293 
  Analysis of individual components of gene sets that are 
activated in the CHF1/Hey2 transgenic myocytes only in the 
absence of serum reveals a number of interesting proteins 
that regulate the function and/or transport of other proteins. 
Genes involved in regulation of transcription factor activity 
(GO: 0051090) include UBE2N, SUMO1, ABRA, 
COMMD7, PRDX3, JMY and MALT1. These molecules 
can regulate the activity of important transcriptional activa-
tors or coactivators, such as p53 (SUMO1), HIF1 
(SUMO1), SRF (ABRA), p300 (JMY) and NF-kB (UBE2N, 
COMMD7, PRDX3, MALT1). Genes involved in protein 
export from the nucleus (GO: 0006611) include XPO7, 
CALR, GSK3B, PRKACA, PTPN11 and DUSP16. XPO7 is 
involved in general export of nuclear proteins, CALR is in-
volved in nuclear export of steroid hormone receptors, while 
GSK3B, PRKACA, PTPN11 and DUSP16 are also involved 
in signal transduction as kinases (GSK3B, PRKACA) or 
phosphatases (PTPN11, DUSP16). Genes involved in steroid 
hormone receptor signaling (GO: 0030518) include MED1, 
JMJD1A, PIAS1, NR3C2, JAK2, MED30, PGR, MED14 
and PPARGC1A. Genes involved in regulation of phos-
phoprotein phosphatase activity include PPP2R4, SAPS2, 
JAK2, SAPS1, SAPS3, RCAN1 and PPP1R2. Increased ex-
pression of these various genes only in the absence of serum 
suggests differences in baseline metabolism of the transgenic 
myocytes, however, their role in cardiac myocyte hypertro-
phy is unclear, as the differences in expression do not persist 
after serum stimulation. 
  Analysis of individual components of gene sets that are 
activated in the CHF1/Hey2 transgenic myocytes after serum 
stimulation reveals a surprising number of genes that play 
roles in autophagy and apoptosis. Genes involved in auto-
phagy (GO: 0016236, GO: 0000045) include ATG4A, 
ATG9A, MAPILC3A, ATG4C, ATG16L1, FRAP1, ATG5, 
and ATG4D (Fig. (7)). Genes involved in apoptosis and cel-
lular component disassembly (GO: 0006309, GO: 0006921, 
GO: 0030262, GO: 0022411) include CECR2, CIDEA, 
CYCS, DFFA, BNIP3 and AIFM1 (Fig. (8)). Genes involved 
in mitochondrial biogenesis (GO: 0007005) include 
NDUFS5, DAP3, VDAC1, DNAJC19, MTX2, MIPEP, 
DCTN6, AIFM2, AIP, FXN, DNAJ3, BNIP3, IMMP2L, 
AIFM1, TIMM8B, TIMM10, TIMM9 and NDUFS8 (Fig. 
(9)). Genes involved in viral reproduction (GO: 0022415) 
include HBXIP, TNIP1, HIPK2, INSR, FURIN, XRCC4, 
XRCC6, CCL5, USF1, WWP1, ITCH, WWP2, NFIA, LIG4 
and SMAD3. Activation of autophagy genes is interesting, 
and is consistent with a protective role for autophagy in the 
heart [26, 27], as previously suggested. Activation of apop-
totic genes is paradoxical, as the transgenic hearts are known 
to be resistant to hypertrophy and apoptosis [28], and may 
reflect a homeostatic feedback loop in response to a down-
stream block to apoptosis. 
DISCUSSION 
  We have previously found that CHF1/Hey2 overexpres-
sion in the myocardium blunts the hypertrophic response 
induced by phenylephrine both in vivo and in vitro [1]. To 
further delineate transcriptional pathways regulated by 
CHF1/Hey2 specifically in cardiac myocytes that are rele-
vant to hypertrophy, we cultured cardiac myocytes from wild 
type and transgenic mice and treated them with serum. As 
expected, transgenic overexpression of CHF1/Hey2 pre-
vented the development of hypertrophy induced by serum. 
We next compared their transcriptomes before and after se-
rum treatment. As described above, we have found that 
CHF1/Hey2 regulates a number of gene sets that may play 
important roles in cardiac hypertrophy.  
  The identification of specific biological processes altered 
by CHF1/Hey2 through Gene Set Analysis reveals both pre-
viously identified and novel pathways that likely affect the 
development of hypertrophy. Numerous microarray studies 
examining the transcriptional profiles in various models of 
hypertrophy have been performed, but consensus findings 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (7). Heat map for genes associated with macroautophagy (GO: 
0016236). Columns represent microarray data obtained from inde-
pendent primary cultures of cells of the indicated genotype and 
therefore represent biological replicates. Gene name abbreviations 
for each component of the gene set are indicated at the end of each 
row. Green indicates expression is lower, while red indicates ex-
pression is higher than average of WT. The genes in this set are 
predominantly upregulated in the transgenic cells (TgS1/2/3/4/5/6/ 
7) in the presence of serum relative to the WT cells treated with 
serum (WTS 1/2/3/4/5/6/7). 294    Current Genomics, 2010, Vol. 11, No. 4  Yu et al. 
have been limited (reviewed in [23]). No specific molecular 
signature for hypertrophy has been described, as transcrip-
tional profiles are divergent in different models of hypertro-
phy [29]. The advantage of Gene Set Analysis and its rela-
tive, Gene Set Enrichment Analysis, is that it more readily 
detects small concordant changes in the expression of genes 
acting in concert, which may alter the flux through a path-
way more readily than a more dramatic change in a single 
gene [18]. A caveat to this method is that the individual 
genes within a gene set may not have significantly different 
gene expression by single gene analysis, and therefore the 
relevance of gene components within each set cannot easily 
be validated. Nevertheless, the method is useful for generat-
ing hypotheses for further experimentation. Using this 
method, we have identified potential roles for genes involved 
in water transport, regulation of adenylate cyclase activity, 
protein dephosphorylation, embryonic development, apopto-
sis and mitochondrial biogenesis, although the exact mecha-
nisms by which these gene products may affect hypertrophy 
will require further study.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (8). Heat map for genes pertaining to apoptotic nuclear 
changes (GO: 0030262). Columns represent microarray data ob-
tained from independent cultures of cells of the indicated genotype 
and therefore represent biological replicates. Gene name abbrevia-
tions for each component of the gene set are indicated at the end of 
each row. Green indicates expression is lower, while red indicates 
expression is higher than average of WT. The genes in this set are 
predominantly upregulated in the transgenic cells (TgS1/2/3/4/5/6/ 
7) in the presence of serum relative to the WT cells treated with 
serum (WTS1/2/3/4/5/6/7). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (9). Heat map for genes involved in mitochondrion organiza-
tion and biogenesis (GO: 0007005). Columns represent microarray 
data obtained from independent cultures of cells of the indicated 
genotype and therefore represent biological replicates. Gene name 
abbreviations for each component of the gene set are indicated at 
the end of each row. Green indicates expression is lower, while red 
indicates expression is higher than average of WT. The genes in 
this set are predominantly upregulated in the transgenic cells 
(TgS1/2/3/4/5/6/7) in the presence of serum relative to the WT cells 
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  A surprising finding of our study is that many genes as-
sociated with autophagy and apoptosis demonstrate in-
creased expression in the transgenic cells after serum stimu-
lation. Autophagy has recently been reported to promote 
heart failure [30], although this finding is controversial and 
directly contradicted by other studies which suggests a pro-
tective role for autophagy in cardiac hypertrophy and pro-
gression to heart failure [26, 27]. Our data is more consistent 
with the latter studies. Increased expression of apoptosis 
related genes is surprising, as we have found that the trans-
genic cells are resistant to apoptosis induced by pressure 
overload or hydrogen peroxide treatment [28]. One possible 
interpretation for this paradoxical finding is that apoptosis is 
inhibited downstream of these molecules, resulting in a ho-
meostatic feedback loop that leads to enhanced expression of 
these proximal genes. Examination of the components of 
these apoptosis related gene sets reveals that the proapoptotic 
gene BAX is downregulated, even though the majority of the 
components are upregulated (Fig. 8). As BAX is a down-
stream effector of mitochondrion-dependent apoptosis, such 
a scenario is plausible. Further experimentation will be re-
quired to explore this hypothesis. 
  One limitation of our study is that we do not have a clear 
idea of the relationship of CHF1/Hey2 to these other genes 
within the context of a gene network. Although we have 
considered performing network analysis on our microarray 
data, we have refrained, as our sample size may not be suffi-
cient in size to conduct a rigorous network analysis with cur-
rent algorithms. In addition, current algorithms make more 
assumptions than are present in our current analysis, which 
may lead to spurious conclusions. In the future, we hope to 
address this important question as algorithms improve and as 
we collect more data. 
CONCLUSIONS 
  We have previously analyzed transcriptional pathways in 
smooth muscle cells lacking CHF1/Hey2 after growth factor 
stimulation to gain insight into CHF1/Hey2-dependent genes 
that determine neointimal formation after vascular injury 
[16, 31]. We have also previously reported that CHF1/Hey2 
can attenuate the hypertrophic response of cardiac myocytes 
to phenylephrine in vivo and in vitro [1]. More recently, we 
have found that CHF1/Hey2 suppresses the development of 
pathological hypertrophy and promotes physiological hyper-
trophy through suppression of apoptosis [28]. Our current 
study examines transcriptional pathways altered in trans-
genic myocytes treated with serum, a potent hypertrophic 
stimulus, and reveals associations between CHF1/Hey2 tran-
scriptional regulation, fluid transport, adenylate cyclase, 
phosphatase activity and a number of other important path-
ways. These aggregate findings underscore the importance of 
CHF1/Hey2 in cardiac hypertrophy, and suggest that future 
therapies based on CHF1/Hey2 may have important thera-
peutic implications in preventing hypertrophy and heart fail-
ure. 
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